Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide-Reference-Cited by-同舟云学术

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide

Published:2010 Issue:2 Volume:45 Page:102
ISSN:1738-7949
Container-title:The Korean Journal of Hematology
language:en
Short-container-title:Korean J Hematol

Author:

Lee Ji Hyun¹,Choi Jimin²,Kwon Kyung A¹,Lee Suee¹,Oh Sung Yong¹,Kwon Hyuk-Chan¹,Kim Hyo-Jin¹,Han Jin Yeong³,Kim Sung-Hyun¹²

Affiliation:

1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.

2. Clinical Research Center, Dong-A University Hospital, Busan, Korea.

3. Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea.

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/kjh.2010.45.2.102

Reference23 articles.

1. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy

2. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen

3. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

4. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation;Transplantation and Cellular Therapy;2023-05

2. Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis;Transplantation and Cellular Therapy;2022-06

3. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis;Bone Marrow Transplantation;2021-09-07

4. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?;The Korean Journal of Internal Medicine;2016-07-01

5. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review;Biology of Blood and Marrow Transplantation;2016-04